Healthcare companies by risk reading
Healthcare companies by risk reading: 1,214 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 1 September 2026.
Composite readings for 8,308 companies, recomputed 1 September 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Mochida Pharmaceutical Co. Ltd MFY | 42 | Elevated | Healthcare | Japan | 5 / 6 | $703M |
| Gushengtang Holdings Limited F2P | 17 | Contained | Healthcare | China | 5 / 6 | $702M |
| Ironwood Pharmaceuticals Inc - Class A IRWD | 40 | Elevated | Healthcare | United States | 4 / 6 | $702M |
| JINXIN FERT.GRP HD-00001 3NX | 58 | Elevated | Healthcare | China | 5 / 6 | $698M |
| Zevra Therapeutics Inc ZVRA | 62 | Stretched | Healthcare | United States | 4 / 6 | $697M |
| Gyre Therapeutics Inc GYRE | 45 | Elevated | Healthcare | United States | 5 / 6 | $697M |
| DocMorris AG DOCM | 67 | Stretched | Healthcare | Switzerland | 5 / 6 | $689M |
| SS Innovations International Inc SSII | 69 | Stretched | Healthcare | India | 4 / 6 | $683M |
| MultiPlan Corp - Class A CTEV | 56 | Elevated | Healthcare | United States | 4 / 6 | $675M |
| Angiodynamic Inc ANGO | 56 | Elevated | Healthcare | United States | 4 / 6 | $673M |
| Evotec SE EVO | 63 | Stretched | Healthcare | Germany | 5 / 6 | $668M |
| Assembly Biosciences Inc ASMB | 35 | Normal | Healthcare | United States | 5 / 6 | $668M |
| Lumibird SA LBIRD | 33 | Normal | Healthcare | France | 5 / 6 | $666M |
| Beijing Tong Ren Tang Chinese Medicine Company Limited TQR | 36 | Normal | Healthcare | Hong Kong | 5 / 6 | $663M |
| Mimedx Group Inc MDXG | 26 | Normal | Healthcare | United States | 5 / 6 | $662M |
| GMR Solutions Inc. GMRS | 42 | Elevated | Healthcare | United States | 4 / 6 | $656M |
| Verastem Inc VSTM | 42 | Elevated | Healthcare | United States | 5 / 6 | $653M |
| VALNEVA AYJ | 87 | Acute | Healthcare | France | 3 / 6 | $651M |
| Prime Medicine Inc PRME | 58 | Elevated | Healthcare | United States | 5 / 6 | $649M |
| CorMedix Inc CRMD | 19 | Contained | Healthcare | United States | 5 / 6 | $642M |
| Aquestive Therapeutics Inc AQST | 75 | Stretched | Healthcare | United States | 5 / 6 | $641M |
| Silence Therapeutics Plc SLN | 69 | Stretched | Healthcare | United Kingdom | 5 / 6 | $639M |
| OmniAb Inc OABI | 65 | Stretched | Healthcare | United States | 4 / 6 | $637M |
| Autolus Therapeutics plc AUTL | 40 | Elevated | Healthcare | United Kingdom | 5 / 6 | $625M |
| Sosei Group Corporation JSS | 62 | Stretched | Healthcare | Japan | 5 / 6 | $622M |
| Cytek BioSciences Inc CTKB | 68 | Stretched | Healthcare | United States | 5 / 6 | $621M |
| Oncology Institute Inc (The) TOI | 39 | Normal | Healthcare | United States | 5 / 6 | $620M |
| OrthoPediatrics Corp KIDS | 54 | Elevated | Healthcare | United States | 5 / 6 | $609M |
| Altimmune Inc ALT | 53 | Elevated | Healthcare | United States | 5 / 6 | $605M |
| Arvinas Inc ARVN | 36 | Normal | Healthcare | United States | 5 / 6 | $601M |
| Evolus Inc EOLS | 51 | Elevated | Healthcare | United States | 5 / 6 | $600M |
| Tilray Brands Inc TLRY | 66 | Stretched | Healthcare | Canada | 4 / 6 | $599M |
| Valneva SE VALN | 79 | Stretched | Healthcare | France | 5 / 6 | $597M |
| ARS Pharmaceuticals Inc SPRY | 68 | Stretched | Healthcare | United States | 5 / 6 | $597M |
| Weave Communications Inc WEAV | 44 | Elevated | Healthcare | United States | 5 / 6 | $584M |
| Nanosonics Ltd NAN | 29 | Normal | Healthcare | Australia | 4 / 6 | $583M |
| Brainsway Ltd BWAY | 25 | Normal | Healthcare | Israel | 5 / 6 | $583M |
| Beauty Farm Medical and Health Industry Inc. XC5 | 28 | Normal | Healthcare | China | 5 / 6 | $581M |
| Pharmagest Interactive SA PHF | 33 | Normal | Healthcare | France | 4 / 6 | $571M |
| Delcath Systems Inc DCTH | 13 | Contained | Healthcare | United States | 5 / 6 | $570M |
| RaySearch Laboratories AB (publ) RAY-B | 20 | Normal | Healthcare | Sweden | 4 / 6 | $563M |
| Fulgent Genetics Inc FLGT | 76 | Stretched | Healthcare | United States | 5 / 6 | $533M |
| Cerus Corp CERS | 57 | Elevated | Healthcare | United States | 4 / 6 | $532M |
| Boiron SA BOI | 43 | Elevated | Healthcare | France | 5 / 6 | $525M |
| OCUMENSION THER.DL-00001 5DG | 47 | Elevated | Healthcare | China | 5 / 6 | $522M |
| Tactile Systems Technology Inc TCMD | 29 | Normal | Healthcare | United States | 5 / 6 | $522M |
| Shofu Inc. 69W | 43 | Elevated | Healthcare | Japan | 4 / 6 | $520M |
| Ion Beam Applications SA IBAB | 42 | Elevated | Healthcare | Belgium | 4 / 6 | $518M |
| Regenxbio Inc RGNX | 53 | Elevated | Healthcare | United States | 5 / 6 | $515M |
| Evolent Health Inc - Class A EVH | 63 | Stretched | Healthcare | United States | 4 / 6 | $507M |
| Charming Medical Ltd - Class A MCTA | 42 | Elevated | Healthcare | Hong Kong | 5 / 6 | $504M |
| XOMA Corp XOMA | 35 | Normal | Healthcare | United States | 4 / 6 | $504M |
| NeuroPace Inc NPCE | 45 | Elevated | Healthcare | United States | 5 / 6 | $502M |
| Strata Critical Medical Inc Cl A Com SRTA | 38 | Normal | Healthcare | United States | 5 / 6 | $501M |
| Ovid Therapeutics Inc OVID | 39 | Normal | Healthcare | United States | 5 / 6 | $493M |
| Valerio Therapeutics ALVIO | 44 | Elevated | Healthcare | France | 5 / 6 | $492M |
| Tong Ren Tang Technologies Co. Ltd TNG | 36 | Normal | Healthcare | China | 5 / 6 | $490M |
| Senseonics Holdings Inc SENS | 41 | Elevated | Healthcare | United States | 5 / 6 | $488M |
| YIDU TECH INC. DL -00002 0EL | 58 | Elevated | Healthcare | China | 5 / 6 | $487M |
| Prothena Corporation plc PRTA | 65 | Stretched | Healthcare | Ireland | 4 / 6 | $484M |
| Polynovo Ltd MFJ | 31 | Normal | Healthcare | Australia | 4 / 6 | $480M |
| Jacobio Pharmaceuticals Group Co., Ltd. 77V | 67 | Stretched | Healthcare | China | 5 / 6 | $476M |
| Kamada Ltd KMDA | 29 | Normal | Healthcare | Israel | 5 / 6 | $475M |
| Editas Medicine Inc EDIT | 54 | Elevated | Healthcare | United States | 4 / 6 | $470M |
| Puma Biotechnology Inc PBYI | 34 | Normal | Healthcare | United States | 4 / 6 | $466M |
| Sight Sciences Inc SGHT | 61 | Stretched | Healthcare | United States | 5 / 6 | $465M |
| GPI S.p.A. Z44 | 29 | Normal | Healthcare | Italy | 5 / 6 | $464M |
| National Research Corp NRC | 43 | Elevated | Healthcare | United States | 5 / 6 | $464M |
| Shanghai Haohai Biological Technology Co. Ltd 5HB | 40 | Elevated | Healthcare | China | 5 / 6 | $463M |
| ClearPoint Neuro Inc CLPT | 68 | Stretched | Healthcare | United States | 4 / 6 | $462M |
| Crescent Biopharma Inc CBIO | 54 | Elevated | Healthcare | United States | 4 / 6 | $461M |
| Evommune Inc EVMN | 48 | Elevated | Healthcare | United States | 5 / 6 | $459M |
| Ocugen Inc OCGN | 59 | Elevated | Healthcare | United States | 5 / 6 | $451M |
| Prelude Therapeutics Inc PRLD | 48 | Elevated | Healthcare | United States | 5 / 6 | $447M |
| Carlsmed Inc CARL | 67 | Stretched | Healthcare | United States | 5 / 6 | $444M |
| Allergy Therapeutics AGY | 81 | Acute | Healthcare | United Kingdom | 5 / 6 | $437M |
| BioAge Labs Inc BIOA | 68 | Stretched | Healthcare | United States | 4 / 6 | $435M |
| Avacta Group PLC AVCT | 69 | Stretched | Healthcare | United Kingdom | 5 / 6 | $432M |
| Fennec Pharmaceuticals Inc FENC | 42 | Elevated | Healthcare | United States | 4 / 6 | $429M |
| Peijia Medical Limited 4WO | 45 | Elevated | Healthcare | China | 5 / 6 | $429M |
| Pacific Biosciences of California Inc PACB | 74 | Stretched | Healthcare | United States | 4 / 6 | $423M |
| Canopy Growth Corporation CGC | 65 | Stretched | Healthcare | Canada | 5 / 6 | $420M |
| Arcturus Therapeutics Holdings Inc ARCT | 73 | Stretched | Healthcare | United States | 5 / 6 | $420M |
| China Resources Medical Holdings Company Limited 1515.HK | 36 | Normal | Healthcare | China | 5 / 6 | $419M |
| Ginkgo Bioworks Holdings Inc - Class A DNA | 61 | Stretched | Healthcare | United States | 5 / 6 | $413M |
| Community Health Systems Inc CYH | 44 | Elevated | Healthcare | United States | 5 / 6 | $412M |
| Cross Country Healthcares Inc CCRN | 57 | Elevated | Healthcare | United States | 5 / 6 | $411M |
| C4 Therapeutics Inc CCCC | 47 | Elevated | Healthcare | United States | 5 / 6 | $410M |
| CellaVision AB CEVI | 38 | Normal | Healthcare | Sweden | 4 / 6 | $409M |
| PureTech Health Plc PRTC | 40 | Elevated | Healthcare | United States | 5 / 6 | $408M |
| LNA Sante SA LNA | 37 | Normal | Healthcare | France | 5 / 6 | $405M |
| 908 Devices Inc MASS | 63 | Stretched | Healthcare | United States | 4 / 6 | $403M |
| M1 Kliniken AG M12 | 26 | Normal | Healthcare | Germany | 5 / 6 | $401M |
| ALLERGY THER. PLC LS-001 HHU | 81 | Acute | Healthcare | United Kingdom | 5 / 6 | $400M |
| JCR Pharmaceuticals Co., Ltd. JCR | 52 | Elevated | Healthcare | Japan | 5 / 6 | $396M |
| IVF Hartmann Holding AG VBSN | 32 | Normal | Healthcare | Switzerland | 5 / 6 | $394M |
| Computer Programs & Systems Inc TBRG | 45 | Elevated | Healthcare | United States | 5 / 6 | $394M |
| NIOX Group PLC NIOX | 20 | Normal | Healthcare | United Kingdom | 5 / 6 | $391M |
| ProKidney Corp - Class A PROK | 53 | Elevated | Healthcare | United States | 5 / 6 | $389M |
| X4 Pharmaceuticals Inc XFOR | 45 | Elevated | Healthcare | United States | 5 / 6 | $388M |
By sector
Industrials 1,536Technology 1,292Healthcare 1,214Consumer Cyclical 1,116Basic Materials 577Communication Services 565Real Estate 552Consumer Defensive 536Energy 356Utilities 232
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.